10x Genomics, Inc.
MX ˙ BMV ˙ US88025U1097
SecurityMX:TXG / 10x Genomics, Inc.
InstitutionMorgan Stanley
Latest Disclosed Ownership3,630,398 shares
Ownership 3.50%
Morgan Stanley ownership in TXG / 10x Genomics, Inc.

2023-12-08 - Morgan Stanley has filed an SC 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 3,630,398 shares of 10x Genomics, Inc. (MX:TXG). This represents 3.5 percent ownership of the company. In their previous filing dated 2023-07-10 , Morgan Stanley had reported owning 5,139,461 shares, indicating a decrease of -29.36 percent.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File
Date		Effective
Date		Form Prev
Shares		 Latest
Shares		 ΔShares
(Percent)		 Ownership
(Percent)		 ΔOwnership
(Percent)
2023-12-08 2023-12-08 13G/A 5,139,461 3,630,398 -29.36 3.50 -32.69
2023-07-10 2023-07-10 13G/A 9,894,979 5,139,461 -48.06 5.20 -50.00
2023-02-08 2023-02-08 13G/A 10,341,753 9,894,979 -4.32 10.40 -4.59
2022-09-12 2022-09-12 13G/A 4,608,758 10,341,753 124.39 10.90 118.00
2022-02-09 2022-02-09 13G/A 5,915,534 4,608,758 -22.09 5.00 -32.43
2021-02-10 2021-02-10 13G/A 6,792,818 5,915,534 -12.91 7.40 -38.84
2020-05-08 2020-05-08 13G/A 5,018,246 6,792,818 35.36 12.10 -48.73
2020-04-09 2020-04-09 13G/A 1,070,491 5,018,246 368.78 23.60 362.75
2020-02-12 2020-02-12 13G 1,070,491 5.10

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F 10X GENOMICS CL A COM 88025U109 2,656,353 -540,540 -16.91 56,394 8.16 0.0034
2026-05-27 2025-12-31 13F/A-1 10X GENOMICS CL A COM 88025U109 3,196,893 379,651 13.48 52,141 58.32 0.0031
2026-02-13 2025-12-31 13F 10X GENOMICS CL A COM 88025U109 3,196,893 379,651 52,141 0.0031
2026-05-27 2025-09-30 13F/A-1 10X GENOMICS CL A COM 88025U109 2,817,242 -669,713 -19.21 32,934 -18.44 0.0020
2025-11-14 2025-09-30 13F 10X GENOMICS CL A COM 88025U109 2,817,242 -669,713 32,934 0.0020
2025-08-15 2025-06-30 13F 10X GENOMICS CL A COM 88025U109 3,486,955 712,864 25.70 40,379 66.73 0.0026
2025-05-15 2025-03-31 13F 10X GENOMICS CL A COM 88025U109 2,774,091 -1,151,180 -29.33 24,218 -57.04 0.0017
2025-05-15 2024-12-31 13F/A-1 10X GENOMICS CL A COM 88025U109 3,925,271 -2,551,036 -39.39 56,367 -61.46 0.0039
2025-02-14 2024-12-31 13F 10X GENOMICS CL A COM 88025U109 3,925,271 -2,551,036 56,367 0.0039
2025-05-14 2024-09-30 13F/A-2 10X GENOMICS CL A COM 88025U109 6,476,307 702,439 12.17 146,235 30.22 0.0106
2025-02-14 2024-09-30 13F/A-1 10X GENOMICS CL A COM 88025U109 6,476,307 702,439 146,235 0.0106
2024-11-14 2024-09-30 13F 10X GENOMICS CL A COM 88025U109 6,476,307 702,439 146,235 0.0013
2025-05-14 2024-06-30 13F/A-2 10X GENOMICS CL A COM 88025U109 5,773,868 609,361 11.80 112,302 -42.06 0.0087
2024-10-17 2024-06-30 13F/A-1 10X GENOMICS CL A COM 88025U109 5,773,868 609,361 112,302 0.0087
2024-08-14 2024-06-30 13F 10X GENOMICS CL A COM 88025U109 5,773,868 609,361 112,302 0.0087
2024-10-17 2024-03-31 13F/A-2 10X GENOMICS CL A COM 88025U109 5,164,507 985,092 23.57 193,824 -17.13 0.0156
2024-08-16 2024-03-31 13F/A-1 10X GENOMICS CL A COM 88025U109 5,164,507 985,092 193,824 0.0018
2024-05-15 2024-03-31 13F 10X GENOMICS CL A COM 88025U109 5,164,507 985,092 193,824 0.0156
2024-08-16 2023-12-31 13F/A-1 10X GENOMICS CL A COM 88025U109 4,179,415 -170,635 -3.92 233,880 30.34 0.0206
2024-02-13 2023-12-31 13F 10X GENOMICS CL A COM 88025U109 4,179,415 -170,635 233,880 0.0206
2023-11-15 2023-09-30 13F 10X GENOMICS CL A COM 88025U109 4,350,050 -1,298,035 -22.98 179,440 -43.11 0.0182
2023-08-14 2023-06-30 13F 10X GENOMICS CL A COM 88025U109 5,648,085 -4,872,606 -46.31 315,389 -46.27 0.0311
2023-05-15 2023-03-31 13F 10X GENOMICS CL A COM 88025U109 10,520,691 200,995 1.95 586,949 56.08 0.0629
2023-02-14 2022-12-31 13F 10X GENOMICS CL A COM 88025U109 10,319,696 -107,676 -1.03 376,050 26.63 0.0427
2022-11-14 2022-09-30 13F 10X GENOMICS CL A COM 88025U109 10,427,372 1,530,496 17.20 296,971 -26.23 0.0405
2022-10-27 2022-06-30 13F/A-1 10X GENOMICS CL A COM 88025U109 8,896,876 -404,980 -4.35 402,583 -43.11 0.0523
2022-08-15 2022-06-30 13F 10X GENOMICS CL A COM 88025U109 8,896,876 -404,980 402,583 0.0523
2022-10-27 2022-03-31 13F/A-1 10X GENOMICS CL A COM 88025U109 9,301,856 4,443,059 91.44 707,592 -2.23 0.0954
2022-05-13 2022-03-31 13F 10X GENOMICS CL A COM 88025U109 9,301,856 4,443,059 707,592 0.0954
2022-02-14 2021-12-31 13F 10X GENOMICS CL A COM 88025U109 4,858,797 -1,216,315 -20.02 723,768 -18.16 0.0894
2021-11-15 2021-09-30 13F 10X GENOMICS CL A COM 88025U109 6,075,112 1,747,269 40.37 884,415 4.36 0.1191
2021-08-23 2021-06-30 13F/A-1 10X GENOMICS CL A COM 88025U109 4,327,843 191,777 4.64 847,479 13.20 0.1118
2021-08-16 2021-06-30 13F 10X GENOMICS CL A COM 88025U109 4,327,843 191,777 847,479 0.0232
2021-05-17 2021-03-31 13F 10X GENOMICS CL A COM 88025U109 4,136,066 -2,570,353 -38.33 748,629 -21.17 0.1100
2021-02-16 2020-12-31 13F 10X GENOMICS CL A COM 88025U109 6,706,419 -3,000,124 -30.91 949,628 -21.53 0.1467
2020-11-13 2020-09-30 13F 10X GENOMICS CL A COM 88025U109 9,706,543 1,485,146 18.06 1,210,211 64.82 0.2341
2020-08-14 2020-06-30 13F 10X GENOMICS CL A COM 88025U109 8,221,397 3,172,819 62.85 734,253 133.37 0.1625
2020-05-26 2020-03-31 13F/A-1 10X GENOMICS CL A COM 88025U109 5,048,578 3,958,168 363.00 314,628 278.41 0.0855
2020-05-15 2020-03-31 13F 10X GENOMICS CL A COM 88025U109 5,048,578 3,958,168 314,628 85,346.4299
2020-02-14 2019-12-31 13F 10X GENOMICS CL A COM 88025U109 1,090,410 633,927 138.87 83,144 261.39 0.0193
2019-11-14 2019-09-30 13F 10X GENOMICS CL A COM 88025U109 456,483 456,483 23,007 0.0061
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.